SCHEMBL3594785

SCHEMBL3594785

N=C(N)Nc1nc(-c2ccc(O)cc2)cs1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.65
AMY1A P0DUB6 4/20 0.65
ALOX15 P16050 3/20 0.65
SMN1; SMN2 Q16637 3/20 0.65
ALDH1A1 P00352 3/20 0.65
TSHR P16473 2/20 0.65
TDP1 Q9NUW8 2/20 0.65
THRB P10828 2/20 0.65
HSD17B10 Q99714 2/20 0.65
GAA P10253 2/20 0.65
USP2 O75604 1/20 0.65
LMNA P02545 1/20 0.65
HPGD P15428 1/20 0.65
ALOX12 P18054 1/20 0.65
HTT P42858 1/20 0.65
NPSR1 Q6W5P4 1/20 0.65
ALOX5 P09917 8/20 0.61
VCP P55072 6/20 0.57
MEN1 O00255 4/20 0.57
KMT2A Q03164 4/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3604799 0.88 ALOX5 (0.61) MAPTAMY1AALOX15SMN1; SMN2ALDH1A1
SCHEMBL3610442 0.86 ALOX5 (0.59) MAPTSMN1; SMN2ALDH1A1TDP1LMNA
SCHEMBL3610890 0.86 MAPT (0.64) MAPTAMY1AALOX15SMN1; SMN2ALDH1A1
SCHEMBL30660071 0.86 MAPT (0.48) MAPTAMY1AALOX15SMN1; SMN2ALDH1A1
SCHEMBL3602636 0.86 ABL1 (0.65) MAPTAMY1AALOX15SMN1; SMN2ALDH1A1
SCHEMBL3603727 0.86 GSTO1 (0.60) MAPTAMY1ASMN1; SMN2ALDH1A1TDP1
SCHEMBL3598628 0.86 MAPT (0.58) MAPTAMY1AALOX15SMN1; SMN2ALDH1A1
SCHEMBL3603436 0.86 MEN1 (0.61) MAPTAMY1AALOX15SMN1; SMN2ALDH1A1
Bromide SCHEMBL7330009 0.84 MEN1 (0.59) MAPTAMY1AALOX15SMN1; SMN2ALDH1A1
SCHEMBL3607468 0.84 ABL1 (0.51) MAPTAMY1AALOX15SMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100298340-A1 Thiazol-Guanidine Derivatives Useful As A (Beta)-Related Pathologies ASTRAZENECA AB (SE) 2010-11-25 US claimed
CN-101466692-A Thiazol-guanidine derivatives useful as a (beta) - related pathologies ASTRAZENECA AB (SE) 2009-06-24 CN claimed
EP-2010508-A1 THIAZOL-GUANIDINE DERIVATIVES USEFUL AS A (BETA)- RELATED PATHOLOGIES AstraZeneca AB (SE) 2009-01-07 EP claimed
WO-2007120096-A1 THIAZOL-GUANIDINE DERIVATIVES USEFUL AS A (BETA)- RELATED PATHOLOGIES ASTRAZENECA AB (SE) 2007-10-25 WO claimed
US-20100298340-A1 Thiazol-Guanidine Derivatives Useful As A (Beta)-Related Pathologies ASTRAZENECA AB (SE) 2010-11-25 US disclosed
CN-101466692-A Thiazol-guanidine derivatives useful as a (beta) - related pathologies ASTRAZENECA AB (SE) 2009-06-24 CN disclosed
EP-2010508-A1 THIAZOL-GUANIDINE DERIVATIVES USEFUL AS A (BETA)- RELATED PATHOLOGIES AstraZeneca AB (SE) 2009-01-07 EP disclosed
WO-2007120096-A1 THIAZOL-GUANIDINE DERIVATIVES USEFUL AS A (BETA)- RELATED PATHOLOGIES ASTRAZENECA AB (SE) 2007-10-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100298340-A1 Thiazol-Guanidine Derivatives Useful As A (Beta)-Related Pathologies GRN, MAPT, GUCY1B1 MAPT 2/4885AMY1A 633/4885ALOX15 4321/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.